Scilex Holding Company
NASDAQ:SCLX
| Market Cap (Intraday) | 120.35M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | 5.71 |
| 10-Day MA | $17.87 |
| 50-Day MA | $11.92 |
| 200-Day MA | $11.80 |
Scilex Holding Company Stock, NASDAQ:SCLX
960 San Antonio Road, 1 Habourfront Avenue, Palo Alto, California 94303
United States of America
Phone: +1.650.516.4310
Number of Employees: 105
Description
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.